Cargando…

Factors Associated With Edoxaban Concentration Among Patients With Atrial Fibrillation

Background and Purpose: Edoxaban exposure varies across different ethnicities. The purpose of our study was to examine the risk factors associated with high or low edoxaban concentrations in Asian populations. Methods: Participants with atrial fibrillation who were undergoing edoxaban therapy were e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Shin-Yi, Kuo, Ching-Hua, Ho, Li-Ting, Liu, Yen-Bin, Huang, Chih-Fen, Tang, Sung-Chun, Jeng, Jiann-Shing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8458830/ https://www.ncbi.nlm.nih.gov/pubmed/34566659 http://dx.doi.org/10.3389/fphar.2021.736826

Ejemplares similares

Measurement of Dabigatran Concentration Using Finger Prick Dried Blood Spot Sample Collection
por: Lin, Shin-Yi, et al.
Publicado: (2021)

Real‐World Rivaroxaban and Apixaban Levels in Asian Patients With Atrial Fibrillation
por: Lin, Shin‐Yi, et al.
Publicado: (2019)

Beneficial Effect of Edoxaban on Preventing Atrial Fibrillation and Coagulation by Reducing Inflammation via HBG1/HBD Biomarkers
por: Yang, Chenguang, et al.
Publicado: (2022)

Impact of different renal function equations on direct oral anticoagulant concentrations
por: Lin, Shin-Yi, et al.
Publicado: (2021)

Identification of Atrial Fibrillation by Quantitative Analyses of Fingertip Photoplethysmogram
por: Tang, Sung-Chun, et al.
Publicado: (2017)

Long-term comparative effectiveness and safety of dabigatran, rivaroxaban, apixaban and edoxaban in patients with atrial fibrillation: A nationwide cohort study
por: Grymonprez, Maxim, et al.
Publicado: (2023)

Effectiveness and safety of edoxaban versus warfarin in patients with nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies
por: Alsultan, Mohammed M., et al.
Publicado: (2023)

Plasma Concentration and Pharmacodynamics of Edoxaban in Patients with Nonvalvular Atrial Fibrillation and Acute Heart Failure
por: Nabeta, Takeru, et al.
Publicado: (2021)

Hemoptysis in Quadriplegia with Atrial Fibrillation Who Was Taking Edoxaban: a Case Report
por: Jeong, Hoyoung, et al.
Publicado: (2021)

Early experiences with edoxaban for stroke prevention in atrial fibrillation in the Southeast Asia region
por: Diaz, Alejandro Bimbo, et al.
Publicado: (2023)

Edoxaban Monotherapy in Nonvalvular Atrial Fibrillation Patients with Coronary Artery Disease
por: Fukamachi, Daisuke, et al.
Publicado: (2022)

Comparison of Once-Daily Administration of Edoxaban and Rivaroxaban in Asian Patients with Atrial Fibrillation
por: Lee, So-Ryoung, et al.
Publicado: (2019)

Outcomes of On-Label Reduced-Dose Edoxaban in Patients With Atrial Fibrillation: The LEDIOS Registry
por: Kim, Ju Youn, et al.
Publicado: (2022)

Impact of Renal Function on Anti-factor Xa Activity Concentrations with Edoxaban Use in Patients with Non-valvular Atrial Fibrillation
por: Ono, Ryohei, et al.
Publicado: (2022)

Clinical Events with Edoxaban in South Korean and Taiwanese Atrial Fibrillation Patients in Routine Clinical Practice
por: Choi, Eue-Keun, et al.
Publicado: (2021)

A Prospective Study to Evaluate the Effectiveness of Edoxaban for the Resolution of Left Atrial Thrombosis in Patients with Atrial Fibrillation
por: Patti, Giuseppe, et al.
Publicado: (2022)

Life-threatening pericardial bleed complicating atrial fibrillation ablation associated with edoxaban therapy successfully managed with prothrombin complex concentrate
por: Choudhury, Moinuddin, et al.
Publicado: (2019)

Cost-Effectiveness of Anticoagulation in Patients with Nonvalvular Atrial Fibrillation with Edoxaban Compared to Warfarin in Germany
por: Krejczy, Martin, et al.
Publicado: (2015)

Cost-Effectiveness Analysis of Apixaban Versus Edoxaban in Patients with Atrial Fibrillation for Stroke Prevention
por: Oyagüez, Itziar, et al.
Publicado: (2019)

Atrial fibrillation trial to evaluate real-world procedures for their utility in helping to lower stroke events: A randomized clinical trial
por: Huang, Wen-Yi, et al.
Publicado: (2020)

An evidence-based review of edoxaban and its role in stroke prevention in patients with nonvalvular atrial fibrillation
por: Acharya, Tushar, et al.
Publicado: (2015)

Edoxaban in Atrial Fibrillation and Venous Thromboembolism—Ten Key Questions and Answers: A Practical Guide
por: De Caterina, Raffaele, et al.
Publicado: (2017)

Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF–TIMI 48 Trial
por: Kato, Eri Toda, et al.
Publicado: (2016)

Edoxaban: A Comprehensive Review of the Pharmacology and Clinical Data for the Management of Atrial Fibrillation and Venous Thromboembolism
por: Stacy, Zachary A., et al.
Publicado: (2016)

Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial
por: Hohnloser, Stefan H, et al.
Publicado: (2019)

Edoxaban Versus Low-Molecular-Weight Heparin in Hospitalized COVID-19 Patients With Atrial Fibrillation
por: Olivera, Pável, et al.
Publicado: (2023)

Influence of ABCB1 Gene Polymorphism on Rivaroxaban Blood Concentration and Hemorrhagic Events in Patients With Atrial Fibrillation
por: Wang, Yan, et al.
Publicado: (2021)

Influenza vaccination and risk of atrial fibrillation in patients with gout: A nationwide population-based cohort study
por: Chen, Chun-Chao, et al.
Publicado: (2022)

Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe)
por: De Caterina, Raffaele, et al.
Publicado: (2019)

An instrument to measure atrial fibrillation knowledge in Chinese patients: validation of the Jessa Atrial fibrillation Knowledge Questionnaire
por: Chang, Sijie, et al.
Publicado: (2023)

Cost-effectiveness of edoxaban versus rivaroxaban for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) in the US
por: Miller, Jeffrey D, et al.
Publicado: (2016)

Corrigendum to: Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial
Publicado: (2019)

Edoxaban Exposure in Patients With Atrial Fibrillation and Estimated Creatinine Clearance Exceeding 100 mL/min
por: Yin, Ophelia, et al.
Publicado: (2021)

Edoxaban for stroke prevention in atrial fibrillation and age-adjusted predictors of clinical outcomes in routine clinical care
por: Kirchhof, Paulus, et al.
Publicado: (2022)

Edoxaban in patients with non-valvular atrial fibrillation after percutaneous coronary intervention: ENCOURAGE-AF design
por: Baldus, Stephan, et al.
Publicado: (2023)

Atrial fibrillation trial to evaluate real-world procedures for their utility in helping to lower stroke events (AFTER-PULSE): Study protocol for a randomized controlled trial
por: Hsieh, Tsung-Ta, et al.
Publicado: (2017)

Honokiol Inhibits Atrial Metabolic Remodeling in Atrial Fibrillation Through Sirt3 Pathway
por: Liu, Guang Zhong, et al.
Publicado: (2022)

Edoxaban versus warfarin in vitamin K antagonist experienced and naïve patients from the edoxaban versus warfarin in subjects undergoing cardioversion of atrial fibrillation (ENSURE-AF) randomised trial
por: Kozieł, Monika, et al.
Publicado: (2020)

Changes in plasma concentrations of edoxaban and coagulation biomarkers according to thromboembolic risk and atrial fibrillation type in patients undergoing catheter ablation: Subanalysis of KYU‐RABLE
por: Shinohara, Tetsuji, et al.
Publicado: (2020)

Safety and Efficacy Re-Evaluation of Edoxaban and Rivaroxaban Dosing With Plasma Concentration Monitoring in Non-Valvular Atrial Fibrillation: With Observations of On-Label and Off-Label Dosing
por: Suwa, Michihiro, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_v6hjvdkj1vh0jlgqsn4j51rv7s